Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038220 (
status epilepticus
)
7,272
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Arginine vasopressin
(
AVP
) has been shown to contribute to the production of seizures. Here, we aimed to investigate the effects of
AVP
on seizures induced by intracerebroventricular (i.c.v.) injection of pilocarpine. Rats were treated with 0.2-2.4 mg/5 microl pilocarpine intracerebroventricularly, to obtain the dose-response relationship for behavioural seizures. 2.4 mg/5 microl pilocarpine induced
status epilepticus
in all rats and 0. 2 mg/5 microl pilocarpine did not produce any sign of seizure in any of the rats. In the second step,
AVP
(0.01-1000 ng/2 microl; i.c.v.) was injected 5 min before i.c.v. injection of a low dose pilocarpine (0.4 mg/5 microl) and rats were observed for percentage of
status epilepticus
,
status epilepticus
latency and behavioural seizure scores. None of the applied doses of
AVP
had any significant effect on seizures induced by 0.4 mg/5 microl i.c.v. pilocarpine. Subcutaneous injection of 1000 ng
AVP
1h before 0.4 mg i.c.v. pilocarpine also did not produce significant difference with respect to the 0.4 mg pilocarpine group. Finally, pretreatment with neither an
AVP
V(1) receptor antagonist (25, 125, 250 ng/5 microl; i.c.v.) nor an
AVP
V(2) receptor antagonist (25, 125, 250 ng/5 microl; i.c.v.) prevented
status epilepticus
, induced by 2.4 mg/5 microl i.c.v. pilocarpine. We conclude that
AVP
does not act as a convulsant agent in centrally-induced pilocarpine seizures.
...
PMID:Arginine vasopressin does not contribute to seizures induced by intracerebroventricularly-injected pilocarpine. 1624 17